| Name | Title | Contact Details |
|---|---|---|
Meina Liang |
Chief Technology Officer | Profile |
GW was co-founded in 1998 by Dr. Geoffrey Guy and Dr. Brian Whittle, two well-known entrepreneurs in the UK biotech sector. In setting up GW, Drs. Guy and Whittle worked closely with both the UK Home Office and the UK`s medicines regulatory authority on establishing necessary licences and procedures so as to facilitate the progress of GW`s cannabinoid research program.
Stern At Home Therapy is transforming how outpatient therapy is experienced.
Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company`s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of six other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada`s rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection and is marketed in the U.S. through a partnership with Kedrion Biopharma. Kamada has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency and, in addition, its intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.
Redmond and Greer Pharmacy Supply is a new and motivated corporation with many iconic brands in our portfolio. Our company began much like many independent pharmacies do, as a family business. Over a short time, the family business evolved into what is now one of the nation`s largest suppliers of niche market prescription medications and related products. Growing is at our heart and products are always changing use our expertise to make sure you`re on the forefront of these new products. Redmond and Greer Pharmacy Supply is a division of The Coney Consulting Group, LLC Our MISSION Our focus is providing value to our customers. We drive value to independent pharmacies by navigating the constantly changing business environment and keeping them in front of new products and profitable opportunities. Our VISION To be the preferred secondary wholesaler to the independent pharmacy market. Our VALUES Being pharmacist owned, we are highly focused on growing the business of the independent pharmacy. Our customers deserve the best, and to provide the best, we deliver all the tools a pharmacy needs to succeed – comprehensive product knowledge, access to pharmaceutical drugs at the best price, and a team that puts service and compliance above all else.
Creyon Bio is a company that is reinventing drug development from the ground up to make safe, effective oligonucleotide based medicines possible—on demand.